Hanx Biopharmaceuticals completes HKD 1.37 million share buyback, boosts treasury stock to 155,800 H-shares

Bulletin Express04-14

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions.

The buyback was executed within a price range of HKD 28.68–30.70 per share, resulting in an aggregate consideration of HKD 1.37 million. The repurchased shares have been retained as treasury stock.

Following the transaction, issued share capital remains at 136.22 million shares, while treasury shares increased to 155,800, representing 0.11 % of the share capital authorised for repurchase under the mandate approved on 12 February 2026. Cumulative buybacks under this mandate now total 155,800 shares, equivalent to 0.11 % of the shares outstanding on the mandate date.

Under Hong Kong Listing Rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 13 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154449304?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154449304","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals completes HKD 1.37 million share buyback, boosts treasury stock to 155,800 H-shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions.</p>\n<p>The buyback was executed within a price range of HKD 28.68–30.70 per share, resulting in an aggregate consideration of HKD 1.37 million. The repurchased shares have been retained as treasury stock.</p>\n<p>Following the transaction, issued share capital remains at 136.22 million shares, while treasury shares increased to 155,800, representing 0.11 % of the share capital authorised for repurchase under the mandate approved on 12 February 2026. Cumulative buybacks under this mandate now total 155,800 shares, equivalent to 0.11 % of the shares outstanding on the mandate date.</p>\n<p>Under Hong Kong Listing Rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 13 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals completes HKD 1.37 million share buyback, boosts treasury stock to 155,800 H-shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals completes HKD 1.37 million share buyback, boosts treasury stock to 155,800 H-shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-14 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions.</p>\n<p>The buyback was executed within a price range of HKD 28.68–30.70 per share, resulting in an aggregate consideration of HKD 1.37 million. The repurchased shares have been retained as treasury stock.</p>\n<p>Following the transaction, issued share capital remains at 136.22 million shares, while treasury shares increased to 155,800, representing 0.11 % of the share capital authorised for repurchase under the mandate approved on 12 February 2026. Cumulative buybacks under this mandate now total 155,800 shares, equivalent to 0.11 % of the shares outstanding on the mandate date.</p>\n<p>Under Hong Kong Listing Rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 13 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1154449304","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154449304","pubTimestamp":1776177774,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions. The buyback was executed within a price range of HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"Hanx Biopharmaceuticals完成137万港元股份回购，库存股增至15.58万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 46,000 H-shares on 13 April 2026 through on-market transactions.\nThe buyback was executed within a price range of HKD 28.68–30.70 per share, resulting in an aggregate consideration of HKD 1.37 million. The repurchased shares have been retained as treasury stock.\nFollowing the transaction, issued share capital remains at 136.22 million shares, while treasury shares increased to 155,800, representing 0.11 % of the share capital authorised for repurchase under the mandate approved on 12 February 2026. Cumulative buybacks under this mandate now total 155,800 shares, equivalent to 0.11 % of the shares outstanding on the mandate date.\nUnder Hong Kong Listing Rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 13 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154449304","isCrawlerRequest":true}